Favipiravir
In SAFARI, favipiravir was administered orally using a high-dose regimen of 6,000 mg on day 1 followed by 1,200 mg twice daily on days 2-10. Before SAFARI, no randomized trial had systematically evaluated favipiravir in humans with Lassa f…
1 sources - 4 claims
In SAFARI, favipiravir was administered orally using a high-dose regimen of 6,000 mg on day 1 followed by 1,200 mg twice daily on days 2-10. Before SAFARI, no randomized trial had systematically evaluated favipiravir in humans with Lassa fever. Favipiravir is a pyrazinecarboxamide antiviral originally developed and registered for influenza. Favipiravir inhibits RNA polymerase across multiple negative-strand RNA viruses.